版本:
中国

BRIEF-Oramed's ORMD-0901 safe and well tolerated in phase IB study

Nov 29 Oramed Pharmaceuticals Inc :

* Oramed's ORMD-0901 (oral GLP-1 analog) found safe and well tolerated in phase IB study

* Oramed Pharmaceuticals Inc - "currently we are preparing to submit an IND with FDA and anticipate initiating a phase IIB study in 2017" Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐